Skip to main content
. 2018 Sep 27;13(4):84–91. doi: 10.5489/cuaj.5142

Table 2.

Patient characteristics and PET/CT results for nodal or distant metastatic disease

Characteristics Positive (n=22) Negative (n=49) p
 Age, years, mean (SD) 68.9 (8.5) 65.4 (7.8) 0.096
 PSA at time of PET/CT, ng/mL, mean (SD) 64.1 (155.8) 24.8 (22.9) 0.086
 PSA, stratified, ng/mL, n (%)
  PSA ≤20 12 (54.5) 28 (57.1) 0.838
  PSA >20 10 (45.5) 21 (42.9)
 cT stage, n (%)
  T1 5 (22.7) 29 (59.2) 0.005
  T2 5 (22.7) 12 (24.5)
  T3 11 (50.0) 8 (16.3)
  T4 1 (4.5) 0 (0.0)
 cN stage, n (%)
  N0 9 (40.9) 43 (87.8) <0.001
  N1 9 (40.9) 2 (4.1)
  Nx 4 (18.2) 4 (8.1)
 Gleason score, n (%)
  6 1 (4.5) 2 (4.1) <0.001
  7 1 (4.5) 9 (18.4)
  8 1 (4.5) 26 (53.1)
  9 18 (81.8) 12 (24.5)
  10 1 (4.5) 0 (0.0)
 Proportion of positive cores on biopsy, % (SD) (NA=1) 74.6 (31.6) 56.0 (26.2) 0.013
 ADT at time of the PET/CT, n (%) (NA=4)
  Yes 5 (22.7) 4 (8.2) 0.110
  No 17 (77.3) 41 (83.7)

ADT: androgen-deprivation therapy; NA: not available; PET/CT: positron-emission tomography-computed tomography; PSA: prostate-specific antigen; SD: standard deviation.